10-Q: DaVita Reports Strong Q2 2026 Growth, Profitability Rises

DaVita Inc. announced robust financial results for the second quarter of 2026, showcasing significant revenue increases and improved operating income.

Summary

• DaVita Inc. reported total revenues of $3.554 billion for Q2 2026, a 5.6% increase year-over-year, and $6.970 billion for the first six months of 2026, up 5.6% from the prior year.
• Net income attributable to DaVita Inc. was $265.4 million for Q2 2026, a substantial increase from $199.3 million in Q2 2025. For the first six months, net income was $462.9 million, up from $362.3 million in the prior year.
• Operating income for the U.S. dialysis segment increased by 4.5% to $1.044 billion for the first six months of 2026.
• Ancillary services revenue grew by 17.0% to $1.054 billion for the first six months of 2026.
• The company's free cash flow significantly increased to $396 million for the first six months of 2026, up from $112 million in the same period of 2025.
• DaVita repurchased 5.2 million shares of common stock for $751 million in the first six months of 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a generally positive report, with solid revenue growth and improved profitability, though some cost pressures and ongoing legal matters warrant attention.

Positives

• Total revenues increased by 5.6% to $6.970 billion for the first six months of 2026 compared to the same period in 2025.
• Net income attributable to DaVita Inc. rose to $462.9 million for the first six months of 2026, a significant improvement from $362.3 million in the prior year.
• Operating income for the U.S. dialysis segment showed a healthy increase of 4.5% to $1.044 billion for the first six months of 2026.
• Ancillary services demonstrated strong growth, with revenues up 17.0% to $1.054 billion for the first six months of 2026.
• Free cash flow saw a substantial increase of 253.6% to $396 million for the first six months of 2026.
• The company's effective income tax rate attributable to DaVita Inc. decreased to 25.4% for the first six months of 2026 from 28.9% in the prior year.
• DaVita successfully managed its U.S. dialysis patient care costs per treatment, which decreased by 1.0% in Q2 2026 compared to Q1 2026.

Negatives

• U.S. dialysis patient care costs per treatment increased by 3.2% for the first six months of 2026 compared to the same period in 2025, driven by increased compensation and insurance costs.
• General and administrative expenses for the U.S. dialysis segment increased by 9.4% for the first six months of 2026 compared to the prior year, primarily due to IT and compensation expenses.
• The company's U.S. dialysis accounts receivable days sales outstanding (DSO) increased to approximately 52 days as of June 30, 2026, from 49 days at December 31, 2025, due to timing of collections.
• International operating income decreased by 17.9% for the first six months of 2026 compared to the prior year, mainly due to a loss on sale of divested centers and increased compensation expense.

Risks

• The company faces ongoing legal and regulatory scrutiny, including investigations by the U.S. Attorney's Office, the California Department of Insurance, the District of Columbia Office of Attorney General, and the Federal Trade Commission.
• Potential impacts from federal government policy changes, including reimbursement rates for Medicare, Medicare Advantage, and Medicaid programs.
• Supply chain challenges and disruptions could increase costs or affect the availability of critical clinical supplies.
• Increased competition from existing and new entrants in the dialysis and pre-dialysis marketplace.
• Risks associated with laws, regulations, and evolving healthcare policies that could impact coverage or reimbursement rates.
• The company's ability to successfully implement its Integrated Kidney Care (IKC) and value-based care (VBC) initiatives.
• Elevated teammate turnover or labor costs, and challenges in attracting and retaining skilled clinical personnel.
• The potential impact of new or innovative technologies, drugs, or other treatments on the dialysis industry.

Future Outlook

The company expects to continue to be impacted by external conditions, including economic, political, and global health factors. Management anticipates productivity improvements to continue throughout the year and expects to begin offering expanded hemodialysis (HD) broadly across its network in the coming quarters. The company believes its cash flow from operations and other liquidity sources will be sufficient to fund its obligations for the foreseeable future.

Management Comments

• The company is continuing to cooperate with the California Department of Insurance in its investigation.
• DaVita disputes the allegations in the fourth amended complaint filed in the U.S. ex rel. Bayne v. DaVita Inc. case and intends to defend this action accordingly.
• DaVita disputes the allegations in the class action complaint in In re Outpatient Medical Center Employee Antitrust Litigation and intends to defend this action accordingly.
• Management believes that the non-GAAP measure of adjusted operating income is useful to investors and analysts in evaluating performance over time and relative to competitors.
• The company believes that its cash flow from operations and other sources of liquidity will be sufficient to fund its scheduled debt service and other obligations for the foreseeable future.

Industry Context

StockSavvy.ai notes that DaVita's performance aligns with a trend of revenue growth in the healthcare services sector, particularly for providers managing chronic conditions. However, increasing patient care costs and regulatory pressures are common industry challenges.

Comparison to Industry Standards

• DaVita's revenue growth of 5.6% for the first six months of 2026 is solid, though specific industry benchmarks for dialysis providers are not detailed in this filing.
• The company's operating margin for its U.S. dialysis segment, while strong, would need to be compared against competitors like Fresenius Medical Care to assess relative performance.
• The increase in patient care costs per treatment (3.2% YTD) is a key metric to monitor against industry trends, which are often influenced by labor and supply costs.
• DaVita's focus on Integrated Kidney Care (IKC) and value-based care (VBC) initiatives reflects a broader industry shift towards more holistic and outcome-based healthcare models.

Legal Proceedings

• Ongoing investigation by the U.S. Attorney's Office, District of New Jersey, related to joint venture arrangements, medical director agreements, and compliance with a Corporate Integrity Agreement.
• The U.S. Attorneys Office for the Eastern District of Pennsylvania is not electing to intervene at this time in the matter of U.S. ex rel. Bayne v. DaVita Inc., et al., which alleges violations of False Claims Acts.
• Investigation by the California Department of Insurance regarding communications with patients about insurance plans and financial assistance from the American Kidney Fund (AKF).
• Investigation by the District of Columbia Office of Attorney General into the AKF, requesting information on communications and donations.
• Investigation by the Federal Trade Commission (FTC) regarding the acquisition of medical director services and provision of dialysis services, focusing on restrictive covenants with physicians.
• A putative class action complaint, In re Outpatient Medical Center Employee Antitrust Litigation, alleging violations of the Sherman Act, for which the court denied the plaintiffs' motion for class certification.
• The company is subject to other various lawsuits, demands, claims, governmental investigations, audits, and legal proceedings, including contractual disputes and employee-related matters.

Related Party Transactions

• The company had a repurchase obligation at June 30, 2026, to purchase shares from Berkshire Hathaway Inc. for $36,513, which was settled on July 31, 2026.

Stakeholder Impact

• Shareholders: Positive impact from increased revenues, net income, and free cash flow, alongside share repurchases. Potential negative impact from ongoing legal risks and cost pressures.
• Employees: Increased compensation expenses noted as a factor in rising patient care costs. Union organizing activities are also mentioned.
• Patients: Continued provision of dialysis and integrated kidney care services. Potential impact from evolving healthcare policies and new treatment options.
• Creditors: Increased long-term debt and associated interest expenses. The company believes its liquidity is sufficient to meet debt obligations.

Next Steps

• Continue to expand patient access to expanded hemodialysis (HD) across the network in the coming quarters.
• Monitor and manage impacts of external conditions, including economic, political, and global health factors.
• Continue to pursue productivity improvements and cost-saving initiatives.
• Address ongoing legal proceedings and regulatory investigations.
• Manage and integrate acquisitions, such as the recent acquisition of a minority interest in Elara Caring.

Key Dates

Recommendation

The filing shows solid revenue and profit growth, indicating operational strength. However, persistent cost pressures, significant ongoing legal and regulatory risks, and the company's substantial debt load warrant a cautious approach. While positives are evident, the uncertainties necessitate a 'hold' recommendation until these risks are more clearly resolved or mitigated.

Keywords

dialysis, kidney care, healthcare services, Medicare, Medicaid, revenue, operating income, financial results